Choroideremia Market to Show Substantial Growth Rate During Forecast Period 2032 – DelveInsight | Key Companies – Biogen, Spark Therapeutics and 4D Molecular Therapeutics (4DMT)


Delveinsight Business Research LLP

DelveInsight’s “Choroideremia Market Insights, Epidemiology, and Market Forecast 2032” report provides an in-depth understanding of the disease, historical and forecast epidemiology, and 7MM choroideremia market size and share (c i.e. USA, EU5 (Germany, Spain, Italy, France and UK) and Japan).

the Choroideremia Market Report covers emerging drugs, current treatment practices, individual therapies market share, current and forecasted market size from 2019 to 2032. It also assesses current treatment practice/algorithm, drivers and barriers of the market and unmet medical needs. opportunities and assess the underlying market potential.

Choroideremia Market

Choroideremia: an overview

Choroideremia is a condition categorized by progressive vision loss that commonly affects males. The first and main symptom of this condition is impaired night vision, also known as night blindness, which can occur in early childhood, along with tunnel vision (a constricted field of vision) and visual activity (capacity decrease to see details). Other names for this condition are: collapsing section, choroidal sclerosis, progressive band choroidal dystrophy and TCD

Choroideremia is inherited in an X-linked recessive pattern. The CHM gene is located on the X chromosome, which is one of the two sex chromosomes. In men (who have only one X chromosome), one altered copy of the gene in each cell is enough to cause the disease.

Key factors driving the choroideremia market

  • According to National Organization for Rare Diseases (NORD), choroideremia mainly affects men. However, a small number of women develop the disease as a result of a genetic process that inactivates the normal gene and leaves only the dysfunctional gene active.

  • According to the article by Kapetanovic et al. (2019), it is estimated that 1 in 50,000 men are affected by choroideremia.

  • According to the National Institute of Health (NIH), the prevalence of choroideremia is estimated at 1 in 50,000 to 100,000 people. However, it is likely that this condition is underdiagnosed due to its similarities to other eye disorders.

  • According to the study by Galvin et al. (2020), the socio-economic impact of hereditary retinal dystrophies (IRDs) in the UK, out of total hereditary retinal diseases (IRDs), the lowest proportion of cases was for choroideremia (1.4%) UK.

Choroideremia Market

Choroideremia Market Size is expected to increase during the forecast period due to the increasing prevalence of choroideremia, as well as the expected launch of emerging therapies such as SPK-7001 from Spark Therapeutics, BIIB111 from Biogen (AAV2-REP1) and 4D-110 from 4D Molecular Therapeutics. the pipeline for choroideremia brings a positive ray of hope for a better treatment model on the market in the years to come.

The market outlook section of the report helps in building a detailed understanding of the historical, current and forecasted. Choroideremia Market Size by analyzing the impact of current and emerging therapies on the market. It also provides a detailed assessment of market drivers and barriers, unmet needs, and emerging technologies.

The report gives full details of the Choroideremia Market Trend for each marketed drug and therapies in late-stage development by assessing their impact based on annual therapy cost, inclusion and exclusion criteria, mechanism of action (MoA), competition with others therapies, brand value, market impact and the vision of key opinion leaders.

Epidemiology of choroideremia

The epidemiology section covers information on historical and current events Choroideremia Patient Group and Predicted Trends for all seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and projected trends by exploring numerous studies and views from key opinion leaders. The epidemiology section also provides the group of diagnosed patients and their trends as well as the assumptions made.

Segmentation of choroideremia epidemiology

  • Total prevalence of choroideremia

  • Prevalence of choroideremia by sex

  • Diagnosed and treatable cases of choroideremia

Choroideremia Drug Adoption and Pipeline Development Activities

The drug absorption section focuses on the absorption rate of potential drugs recently launched in the Choroideremia Market or expected to be launched in the market during the study period. The analysis covers choroideremia drug market adoption; patient adherence to therapies; and sales of each medicine.

The drug uptake section of the report helps in understanding which drugs are absorbing fastest, reasons for maximum usage of new drugs and allows comparison of drugs on the basis of market share and size, which will again be useful for studying important factors in market uptake. and in making financial and regulatory decisions.

The report also covers the Choroideremia Pipeline Development Activities and provides valuable insights into various phase II and phase III therapeutic candidates and the leading market companies involved in the development of targeted therapies. It also analyzes recent development such as collaborations, acquisitions and mergers, patent licensing details and other information on emerging therapies.

Get the sample PDF of the report:- https://www.delveinsight.com/sample-request/choroideremia-market

Therapeutic analysis of choroideremia

Some of the Major Companies in the Choroideremia Market Include:

And many more.

Choroideremia therapies covered in the report include:

  • SPK-7001 (AAV2-hCHM)

  • BIIB111 (AAV2-REP1)

  • 4D-110

And much more.

The launch of these emerging therapies is expected to have a significant impact on the choroideremia treatment scenario in the coming years.

Get more in-depth insights into emerging therapies and key companies:- https://www.delveinsight.com/sample-request/choroideremia-market

Contents

1. Key information

2. Executive Summary

3. Competitive intelligence analysis of choroideremia

4. Choroideremia Market Overview at a Glance

5. Background and Overview of Choroideremia Disease

6. Choroideremia patient journey

7. Epidemiology of choroideremia and patient population

8. Choroideremia Treatment Algorithm, Current Treatment and Medical Practices

9. Unmet needs of choroideremia

10. Key Parameters of Choroideremia Treatment

11. Products marketed for choroideremia

12. Emerging therapies for choroideremia

13. Seven Major Choroideremia Market Analysis

14. Attribute analysis

15. Choroideremia Market Outlook (7 Major Markets)

16. Choroideremia Access and Reimbursement Overview

17. KOL views on the choroideremia market.

18. Choroideremia Market Drivers

19. Choroideremia Market Barriers

20. Appendix

21. DelveInsight Abilities

22. Disclaimer

*The table of contents is not exhaustive; final content may vary.

Request a sample report here:- https://www.delveinsight.com/sample-request/choroideremia-market

Other Latest DelveInsight Reports

Overview of bevacizumab biosimilars

from DelveInsight,”Bevacizumab Biosimilar Insight” report provides comprehensive information about 40+ companies and More than 40 drugs marketed and in development in the landscape of bevacizumab biosimilars. The report also covers profiles of drugs marketed and in development, including clinical and non-clinical stage products.

About DelveInsight

DelveInsight is a leading business consultant and market research company focused exclusively on life sciences. It supports pharmaceutical companies by providing complete end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact: Shruti Thakur
E-mail: Send an email
Call: 9193216187
Address:304 S. Jones Boulevard #2432
Town: Vegas
State: Nevada
The country: United States
Website: https://www.delveinsight.com/

Previous Demographers expect "manageable" employment, population growth in N.Va. | news/arlington
Next Sununu redistricting map for congressional districts sparks concern